High demand causes mumps vaccine shortage in Japan; OncoQCR's breast cancer vax succeeds in nonhuman primates;

> Higher-than-expected demand for the mumps vaccine has caused a shortage in Japan, though the shortfall is expected to be alleviated between next week and the end of November. Story

> OncoQCR's breast cancer vaccine candidate, OQR200, induced high levels of antibodies and T-cell responses to HER2/neu cancer cells in a nonhuman primate study. Release

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.